Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
A partial agonist is a substance that binds to a receptor and activates it but produces a lower maximum response than a full agonist in the same system. Increasing the dose can increase receptor occupancy without producing the full agonist's maximum effect. Its observed response depends on receptor number, tissue signaling, and the presence of other ligands. A partial agonist has both receptor affinity and intrinsic efficacy.
read more about partial agonist ...A partial agonist stabilizes a receptor in an active state but does so less effectively than a full agonist. When no stronger agonist is present, it can produce a meaningful receptor response. When a full agonist is present, the partial agonist can compete for receptors and reduce the overall effect. It can therefore behave as an agonist in one setting and a functional antagonist in another.
Buprenorphine is a partial agonist at the mu opioid receptor and is used for opioid use disorder and pain. Aripiprazole has partial agonist activity at selected dopamine receptors and is used for several psychiatric conditions. Varenicline is a partial agonist at selected nicotinic acetylcholine receptors and supports smoking cessation. The degree of partial activity and clinical effect differs among drugs, receptors, and tissues.
A ceiling effect occurs when increasing the dose beyond a certain point produces little additional receptor-mediated response. This can improve safety for some effects but does not remove all overdose or toxicity risk. Buprenorphine has a ceiling on some opioid effects, particularly respiratory depression, compared with full mu agonists. Other side effects or interactions can continue to increase even when one measured effect has reached a plateau.
A partial agonist can displace a full agonist because receptor affinity and intrinsic activity are separate properties. Buprenorphine can precipitate opioid withdrawal when started too soon after a full opioid agonist. Partial agonists can still cause dependence, sedation, cardiovascular effects, or other drug-specific problems. Dose changes and transitions between agonists require medicine-specific planning and monitoring.
It produces a lower maximum receptor response in the same experimental system. This does not mean that every clinical dose is weak or ineffective.
Yes. In the presence of a full agonist, it can compete for receptors and lower the combined response. Its behavior depends on the surrounding receptor environment.
Yes. Buprenorphine is a partial agonist at the mu opioid receptor and has high receptor affinity. It also has activity at other opioid-receptor subtypes.
No. It can limit selected receptor-mediated effects, but serious toxicity remains possible, especially with alcohol, benzodiazepines, or other central nervous system depressants.
Pharmacodynamics. StatPearls (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK507791/. Date Accessed August 6, 2026.
Buprenorphine. StatPearls (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK459126/. Date Accessed August 6, 2026.
Aripiprazole. StatPearls (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK547739/. Date Accessed August 6, 2026.
Varenicline. StatPearls (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK534846/. Date Accessed August 6, 2026.
Chapter 3D: Buprenorphine. Medications for Opioid Use Disorder (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK574909/. Date Accessed August 6, 2026.